PFE PFIZER INC

NYSE pfizer.com


$ 25.15 $ 0.65 (2.63 %)    

Tuesday, 11-Nov-2025 13:54:20 EST
QQQ $ 622.24 $ 1.62 (0.26 %)
DIA $ 478.86 $ 4.87 (1.03 %)
SPY $ 682.99 $ 3.01 (0.44 %)
TLT $ 89.92 $ -0.03 (-0.03 %)
GLD $ 378.41 $ -1.58 (-0.42 %)
$ 24.39
$ 24.49
$ 25.14 x 1,020
$ 25.15 x 3,746
$ 24.45 - $ 25.20
$ 19.83 - $ 27.21
148,958,624
na
138.67B
$ 0.50
$ 14.11
TBD
na
na ($ 0.07)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-28-2025 10-Q
2 08-05-2025 06-29-2025 10-Q
3 05-05-2025 03-30-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-04-2024 09-29-2024 10-Q
6 08-05-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 11-08-2023 10-01-2023 10-Q
10 08-09-2023 07-02-2023 10-Q
11 05-10-2023 04-02-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-09-2022 10-02-2022 10-Q
14 08-10-2022 07-03-2022 10-Q
15 05-11-2022 04-03-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-12-2021 10-03-2021 10-Q
18 08-12-2021 07-04-2021 10-Q
19 05-13-2021 04-04-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-27-2020 10-Q
22 08-06-2020 06-28-2020 10-Q
23 05-07-2020 03-29-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 11-07-2019 09-29-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-09-2018 07-01-2018 10-Q
31 05-10-2018 04-01-2018 10-Q
32 02-22-2018 12-31-2017 10-K
33 11-09-2017 10-01-2017 10-Q
34 08-10-2017 07-02-2017 10-Q
35 05-11-2017 04-02-2017 10-Q
36 02-23-2017 12-31-2016 10-K
37 11-10-2016 10-02-2016 10-Q
38 08-11-2016 07-03-2016 10-Q
39 05-12-2016 04-03-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cogent-biosciences-lead-cancer-drug-cuts-disease-progression-or-death-risk-by-50-in-stomach-cancer-trial

Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIS...

 pfizer-clinches-10-billion-deal-to-buy-obesity-drug-maker-metsera-outbidding-novo-nordisk-in-fierce-battle-for-weight-loss-market-dominance

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying build...

 eli-lilly-novo-nordisk-make-weight-loss-drugs-more-affordable-via-medicare-medicaid-trumprx

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage...

Core News & Articles

https://www.youtube.com/watch?v=uEpKxwMm8-8

 pfizer-to-raise-metsera-bid-after-court-denies-attempt-to-block-rival-deal

Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a hi...

Core News & Articles

https://www.ft.com/content/52216b29-9f22-4338-85a7-eacfc33103a1

Core News & Articles

https://www.ft.com/content/ae3297f3-4dd1-4c8a-b9c5-9c3717d34c52 

Core News & Articles

"Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restrai...

Core News & Articles

-Reuters Citing Metsera Letter To Court

Core News & Articles

-Reuters Citing Letter To Court

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION